7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Abe M | [Hypercalcemia in myeloma]. | 2007 | Nippon Rinsho | pmid:18069268 |
Udagawa N and Takahashi N | [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. | 2002 | Nippon Rinsho | pmid:11979968 |
Tsuda E | [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. | 2002 | Nippon Rinsho | pmid:11979969 |
Koshihara Y | [Recent progress of bone cell culture system (review)]. | 2002 | Nippon Rinsho | pmid:11979973 |
Sato K | [Graves' disease and bone metabolism]. | 2006 | Nippon Rinsho | pmid:17154099 |
Sato K | [Osteoclast-activating factors (OAF)]. | 2004 | Nippon Rinsho | pmid:15658306 |
Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2010 | Nippon Rinsho | pmid:20960766 |
Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
Suzuki Y | [Clinical significance of biomarkers in diagnosis of metabolic bone diseases]. | 2007 | Nippon Naika Gakkai Zasshi | pmid:18044149 |
Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
Tanaka Y and Okada Y | [Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms]. | 2007 | Nippon Naika Gakkai Zasshi | pmid:17506302 |
Kozaki K | [Current concepts of vascular calcification]. | 2005 | Nihon Ronen Igakkai Zasshi | pmid:16408509 |
Kaneko K and Kawai S | [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. | 2011 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:21720102 |
Tanaka Y et al. | [Mesenchymal stem cells for the treatment and repair of inflammatory arthritis]. | 2015 | Nihon Rinsho Meneki Gakkai Kaishi | pmid:26016635 |
Shiota J et al. | [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients]. | 2010 | Nihon Jinzo Gakkai Shi | pmid:21254698 |
Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
Jefferson AL et al. | Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. | 2007 | Neurology | pmid:17389308 |
Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
Sen O et al. | The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. | 2005 | Neurol. Res. | pmid:15949247 |
Kokkotou E et al. | Serum correlates of the placebo effect in irritable bowel syndrome. | 2010 | Neurogastroenterol. Motil. | pmid:20028464 |
Bergestuen DS et al. | Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis. | 2010 | Neuroendocrinology | pmid:20720391 |
Kao SY et al. | Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. | 2013 | Neurobiol. Dis. | pmid:23607938 |
Ozkaya O et al. | Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. | 2007 | Nephron Clin Pract | pmid:17259742 |
Kim HR et al. | The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. | 2013 | Nephron Clin Pract | pmid:23921088 |
Kurnatowska I et al. | Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. | 2011 | Nephron Clin Pract | pmid:20861651 |
Jiang JQ et al. | Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. | 2011 | Nephrology (Carlton) | pmid:21649792 |
Speer G et al. | Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. | 2008 | Nephrol. Dial. Transplant. | pmid:18450827 |
Shroff RC et al. | The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. | 2008 | Nephrol. Dial. Transplant. | pmid:18463323 |
Ford ML et al. | FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. | 2012 | Nephrol. Dial. Transplant. | pmid:21750158 |
Albalate M et al. | Association between phosphate removal and markers of bone turnover in haemodialysis patients. | 2006 | Nephrol. Dial. Transplant. | pmid:16490746 |
Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
Cianciolo G et al. | Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. | 2011 | Nephrol. Dial. Transplant. | pmid:20659908 |
Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
Graciolli FG et al. | Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. | 2009 | Nephrol. Dial. Transplant. | pmid:19075196 |
Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
Sigrist MK et al. | Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. | 2009 | Nephrol. Dial. Transplant. | pmid:19491380 |
Messa P et al. | Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. | 2007 | Nephrol. Dial. Transplant. | pmid:17526536 |
Morena M et al. | A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. | 2009 | Nephrol. Dial. Transplant. | pmid:19574342 |
Svensson M et al. | Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. | 2012 | Nephrol. Dial. Transplant. | pmid:22172725 |
Kazama JJ et al. | Circulating osteoprotegerin is not removed through haemodialysis membrane. | 2002 | Nephrol. Dial. Transplant. | pmid:12271009 |
Nitta K et al. | Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. | 2004 | Nephrol. Dial. Transplant. | pmid:15128884 |
Coen G et al. | Serum osteoprotegerin and renal osteodystrophy. | 2002 | Nephrol. Dial. Transplant. | pmid:11812872 |
Talmor-Barkan Y et al. | Low extracellular Ca2+: a mediator of endothelial inflammation. | 2009 | Nephrol. Dial. Transplant. | pmid:19617602 |
Jablonska E et al. | TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia. | 2008 | Neoplasma | pmid:18190241 |
Scudla V et al. | The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. | 2010 | Neoplasma | pmid:20099972 |
Briana DD et al. | Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. | 2009 | Neonatology | pmid:19365143 |
Schenk-Braat EA and Bangma CH | [The search for better markers for prostate cancer than prostate-specific antigen]. | 2006 | Ned Tijdschr Geneeskd | pmid:16821452 |
Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
Araújo AA et al. | Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. | 2013 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:23775504 |
Kong YY et al. | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. | 1999 | Nature | pmid:10580503 |
Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
Boyle WJ et al. | Osteoclast differentiation and activation. | 2003 | Nature | pmid:12748652 |
Martin TJ and Mundy GR | Bone metastasis: can osteoclasts be excluded? | 2007 | Nature | pmid:17314931 |
Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
Scholtysek C et al. | PPARβ/δ governs Wnt signaling and bone turnover. | 2013 | Nat. Med. | pmid:23542786 |
Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
Movérare-Skrtic S et al. | Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. | 2014 | Nat. Med. | pmid:25306233 |
Geneviève D et al. | Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). | 2008 | Nat. Genet. | pmid:18264100 |
Wagner H | Bone diseases: Interferon regulatory factor-8 suppresses osteoclastogenesis. | 2010 | Nat Rev Rheumatol | pmid:20125173 |
Flyvbjerg A | Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. | 2010 | Nat Rev Endocrinol | pmid:20098449 |
Lacey DL et al. | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. | 2012 | Nat Rev Drug Discov | pmid:22543469 |
Kassi E et al. | Effects of Sideritis euboea (Lamiaceae) aqueous extract on IL-6, OPG and RANKL secretion by osteoblasts. | 2011 | Nat Prod Commun | pmid:22224290 |
Lin J et al. | Increased generation of Foxp3(+) regulatory T cells by manipulating antigen presentation in the thymus. | 2016 | Nat Commun | pmid:26923114 |
Daroszewska A and Ralston SH | Mechanisms of disease: genetics of Paget's disease of bone and related disorders. | 2006 | Nat Clin Pract Rheumatol | pmid:16932700 |
Blair JM et al. | Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. | 2006 | Nat Clin Pract Oncol | pmid:16407878 |
Huang SH et al. | [Guling tablets promotes the proliferation and mineralization and regulates OPG/RANKL/M-CSF expression of osteoblasts via the p38 MAPK pathway in vitro]. | 2008 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:18676248 |
Yang XY et al. | [Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21868322 |
Wang Q et al. | [Effect of estrogen on osteoprotegerin, osteoclast differentiation factor and macrophage colony stimulating factor mRNA expressions in ovariectomized rat bone tissue]. | 2006 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:16624776 |
Zhou XW et al. | [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21945761 |
Wang Y et al. | [Interleukin-4 and osteoprotegerin suppress polyethylene wear debris-induced osteolysis in a murine air pouch model]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:22027773 |
Wang JZ et al. | [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:22027774 |
Dong W et al. | [Effect of alendronate on expressions of osteoprotegerin and receptor activator of nuclear factor κB ligand in mouse osteoblasts]. | 2012 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:23268391 |
Liu ZF et al. | [Effect of ultrasound on osteoprotegerin and receptor activator nuclear factor kappaB ligand expression during root resorption in rats]. | 2011 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:21602131 |
Styrkarsdottir U et al. | Multiple genetic loci for bone mineral density and fractures. | 2008 | N. Engl. J. Med. | pmid:18445777 |
Hirschhorn JN and Gennari L | Bona fide genetic associations with bone mineral density. | 2008 | N. Engl. J. Med. | pmid:18445778 |
Whyte MP et al. | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12124406 |
Krane SM | Genetic control of bone remodeling--insights from a rare disease. | 2002 | N. Engl. J. Med. | pmid:12124412 |
Vegni FE et al. | Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. | 2004 | N. Engl. J. Med. | pmid:14711922 |
Kiechl S et al. | Denosumab, osteoporosis, and prevention of fractures. | 2009 | N. Engl. J. Med. | pmid:19940304 |
Riches PL et al. | Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. | 2009 | N. Engl. J. Med. | pmid:19812402 |
Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
Hofbauer LC et al. | Estrogen therapy and coronary-artery calcification. | 2007 | N. Engl. J. Med. | pmid:17891834 |
Hofbauer LC et al. | High bone density due to a mutation in LDL-receptor-related protein 5. | 2002 | N. Engl. J. Med. | pmid:12240686 |
Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
Deftos LJ | Treatment of Paget's disease--taming the wild osteoclast. | 2005 | N. Engl. J. Med. | pmid:16135831 |
Cundy T et al. | Recombinant osteoprotegerin for juvenile Paget's disease. | 2005 | N. Engl. J. Med. | pmid:16135836 |
Kurban S et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. | 2008 | Mult. Scler. | pmid:18208894 |
Weinstock-Guttman B et al. | Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. | 2006 | Mult. Scler. | pmid:17086898 |
Li N et al. | Inhibitory effects of morinda officinalis extract on bone loss in ovariectomized rats. | 2009 | Molecules | pmid:19513005 |
Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
Chanda D et al. | Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. | 2008 | Mol. Ther. | pmid:18388919 |
Lee JH et al. | Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. | 2010 | Mol. Pharmacol. | pmid:19828731 |
Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
Doschak MR et al. | Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. | 2009 Mar-Apr | Mol. Pharm. | pmid:19718808 |
Yen ML et al. | TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. | 2008 | Mol. Immunol. | pmid:18206242 |
Yamada Y et al. | Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. | 2003 | Mol. Genet. Metab. | pmid:14680982 |
Wang N et al. | Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. | 2012 | Mol. Endocrinol. | pmid:22108801 |
Spelsberg TC et al. | The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. | 1999 | Mol. Endocrinol. | pmid:10379881 |